This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ottaviani G, Jaffe N . The epidemiology of osteosarcoma. Cancer Treat Res 2009; 152: 3–13.
Ta HT, Dass CR, Choong PF, Dunstan DE . Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 2009; 28: 247–263.
Lee JW, Kim H, Kang HJ, Kim HS, Park SH, Kim IO et al. Clinical characteristics and treatment results of pediatric osteosarcoma: the role of high dose chemotherapy with autologous stem cell transplantation. Cancer Res Treat 2008; 40: 172–177.
Whelan J, Seddon B, Perisoglou M . Management of osteosarcoma. Curr Treat Options Oncol 2006; 7: 444–455.
Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011–2018.
Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559–568.
Kim SJ, Yoon DH, Yang DH, Eom HS, Cho SG, Yoon SS et al. Plerixafor use for peripheral blood stem cell mobilization in Korea. Blood Res 2013; 48: 72–73.
Hong KT, Kang HJ, Kim NH, Kim MS, Lee JW, Kim H et al. Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment. J Hematol Oncol 2012; 5: 14.
Fagioli F, Aglietta M, Tienghi A, Ferrari S, Brach del Prever A, Vassallo E et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002; 20: 2150–2156.
Arpaci F, Ataergin S, Ozet A, Erler K, Basbozkurt M, Ozcan A et al. The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma: results of a phase II study. Cancer 2005; 104: 1058–1065.
Jaffe N . Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009; 152: 239–262.
Miniero R, Brach del Prever A, Vassallo E, Nesi F, Busca A, Fagioli F et al. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma. Bone Marrow Transplant 1998; 22 (Suppl 5): S37–S40.
Sauerbrey A, Bielack S, Kempf-Bielack B, Zoubek A, Paulussen M, Zintl F . High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 2001; 27: 933–937.
Boye K, Del Prever AB, Eriksson M, Saeter G, Tienghi A, Lindholm P et al. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study. Pediatr Blood Cancer 2014; 61: 840–845.
Acknowledgements
This research was supported by grant no. 03-2013-0170 from SNUH Research Fund and grant no. 14172MFDS178 from the Ministry of Food and Drug Safety in 2014. The authors alone are responsible for the content and writing of this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Hong, C., Kang, H., Kim, M. et al. High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma. Bone Marrow Transplant 50, 1375–1378 (2015). https://doi.org/10.1038/bmt.2015.145
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.145